Latest news with #SaiLifeSciences
Business Standard
14-05-2025
- Business
- Business Standard
Sai Life Sciences jumps after stellar Q4 results
Sai Life Sciences jumped 4.61% to Rs 759 after the company's net profit surged 105% to Rs 170 crore on 16% increase in revenue fropm operations to Rs 1695 crore in Q4 March 2025 over Q4 March 2024. EBITDA jumped 42% year-on-year (YoY) to Rs 425 crore in Q4FY25. EBITDA margin improved to 25% in Q4 FY25, compared to 20% in Q4 FY24. Profit before tax rose 108% YoY to Rs 228 crore in Q4FY25. For the full year, net profit rose 57% to Rs 88 crore on 32% increase in revenue from operations to Rs 580 crore in the year ended March 2025 over the year ended March 2024. EBITDA rose 30% YoY to Rs 161 crore in FY25. EBITDA margin was unchaged at 28% in FY25. PBT climbed 56% YoY to Rs 119 crore in FY25. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said, "We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders. Siva Chittor, director and chief financial officer, Sai Life Sciences added, "We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders." Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.
Business Standard
14-05-2025
- Business
- Business Standard
Sai Life Sciences consolidated net profit rises 57.26% in the March 2025 quarter
Sales rise 31.94% to Rs 579.51 crore Net profit of Sai Life Sciences rose 57.26% to Rs 88.27 crore in the quarter ended March 2025 as against Rs 56.13 crore during the previous quarter ended March 2024. Sales rose 31.94% to Rs 579.51 crore in the quarter ended March 2025 as against Rs 439.21 crore during the previous quarter ended March 2024. For the full year,net profit rose 105.45% to Rs 170.13 crore in the year ended March 2025 as against Rs 82.81 crore during the previous year ended March 2024. Sales rose 15.66% to Rs 1694.57 crore in the year ended March 2025 as against Rs 1465.18 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 579.51439.21 32 1694.571465.18 16 OPM % 27.1928.38 - 23.9419.48 - PBDT 156.29107.11 46 366.28228.67 60 PBT 118.8076.05 56 227.70109.23 108 NP 88.2756.13 57 170.1382.81 105
Hans India
24-04-2025
- Business
- Hans India
Making pharma deliveries more sustainable
Hyderabad: On Wednesday, DHL Express has partnered with Sai Life Sciences to use DHL's emission-reduced shipping solution – GoGreen Plus (GGP). The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90 per cent for its international logistics needs. Sai Life Sciences works with over 300 global innovator pharma and biotech companies to accelerate the pace of their drug discovery, development and commercialisation. R S Subramanian, senior vice president – South Asia, DHL Express, said, 'Addressing Scope 3 emissions is critical to DHL for achieving the commitment to be carbon neutral by 2050. GoGreen Plus is a pioneering service that helps our customers address Scope 3 carbon emissions of their critical shipments to global destinations.' Sivaramakrishnan Chittor, CFO, Sai Life Sciences added, 'Our partnership with DHL reflects a shared commitment to reducing environmental impact while maintaining the reliability and precision that our customers depend on. It's one more way we're integrating sustainability into how we work – with intent and consistency – to make it better together.'
Yahoo
03-04-2025
- Business
- Yahoo
Sai Life Sciences sets up Peptide Research Center in India
HYDERABAD, India, April 03, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India. Announcing the launch, , said: 'As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics.' The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics. Maneesh Pingle, Head of Discovery Services, said: 'The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.' The new Peptide Research Center will be integrated with Sai Life Sciences' end-to-end discovery services, spanning synthetic and medicinal chemistry, biology, DMPK, and toxicology. This holistic approach ensures seamless transitions across different stages of drug discovery, accelerating timelines and enhancing success rates for peptide-based drug development. By combining deep expertise, cutting-edge technology, and an integrated approach, Sai Life Sciences strengthens its commitment to supporting global clients in advancing innovative peptide therapeutics. About Sai Life Sciences: Sai Life Sciences is an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO) that works with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 25 years, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. The company has over 3,000 employees across its facilities in India, UK, USA and Japan. For further information, contact: Sriram GopalakrishnanVice President, Corporate CommunicationSai Life Sciences LimitedPh: +91 9121295355sriram.g@ A photo accompanying this announcement is available at: in to access your portfolio
